Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 18/20 | 0.74 |
| ▸ | MMP9 | P14780 | 18/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.47 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5131464 | 1.00 | MMP2 (0.74) | MMP2MMP9SMN1; SMN2CRY1CRY2 | |
| SCHEMBL5131397 | 0.89 | MMP2 (0.74) | MMP2MMP9SMN1; SMN2 | |
| SCHEMBL5131359 | 0.89 | MMP2 (0.74) | MMP2MMP9SMN1; SMN2 | |
| SCHEMBL5126468 | 0.89 | MMP2 (0.76) | MMP2MMP9SMN1; SMN2CRY1CRY2 | |
| SCHEMBL5125315 | 0.89 | MMP2 (0.74) | MMP2MMP9 | |
| SCHEMBL5127877 | 0.89 | MMP2 (0.74) | MMP2MMP9 | |
| SCHEMBL8021223 | 0.86 | MMP2 (0.77) | MMP2MMP9 | |
| SCHEMBL8391064 | 0.85 | MMP2 (1.00) | MMP2MMP9 | |
| SCHEMBL5125795 | 0.85 | MMP2 (0.57) | MMP2MMP9SMN1; SMN2 | |
| SCHEMBL8028206 | 0.85 | MMP2 (1.00) | MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080085893-A1 | MATRIX METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085893-A1 | MATRIX METALLOPROTEASE INHIBITORS | MMP3, MMP7, MMP9 | MMP2 5/4885MMP9 3/4885SMN1; SMN2 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.